Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Diagnosis Track

Prognostic value of post-treatment 18F-FDG PET/CT studies in melanoma patients receiving ipilimumab

Hoda Anwar, Christos Sachpekidis, Julia Winkler, Jessica Hassel, Uwe Haberkorn and Antonia Dimitrakopoulou-Strauss
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 1088;
Hoda Anwar
1Clinical Cooperation Unit Nuclear Medicine German Cancer Research Center Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christos Sachpekidis
1Clinical Cooperation Unit Nuclear Medicine German Cancer Research Center Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Winkler
3University Hospital Heidelberg Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Hassel
2National Center for Tumor Diseases Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
4Division of Nuclear Medicine University of Heidelberg Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonia Dimitrakopoulou-Strauss
1Clinical Cooperation Unit Nuclear Medicine German Cancer Research Center Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 58 no. supplement 1 1088

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 24, 2017.

Copyright & Usage 
© 2017

Author Information

  1. Hoda Anwar1,
  2. Christos Sachpekidis1,
  3. Julia Winkler3,
  4. Jessica Hassel2,
  5. Uwe Haberkorn4 and
  6. Antonia Dimitrakopoulou-Strauss1
  1. 1Clinical Cooperation Unit Nuclear Medicine German Cancer Research Center Heidelberg Germany
  2. 2National Center for Tumor Diseases Heidelberg Germany
  3. 3University Hospital Heidelberg Heidelberg Germany
  4. 4Division of Nuclear Medicine University of Heidelberg Heidelberg Germany

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2017 to April 2025

AbstractFullPdf
May 2017400
Jun 20173800
Jul 20171000
Aug 20171900
Sep 20171700
Oct 20172100
Nov 20171500
Dec 2017900
Jan 20181000
Feb 20181200
Mar 20181100
Apr 20181300
May 20181700
Jun 2018600
Jul 20181000
Aug 2018400
Sep 20181000
Oct 20181800
Nov 20181600
Dec 2018900
Jan 2019300
Feb 2019200
Mar 2019200
Apr 2019400
Jun 2019100
Jul 2019200
Oct 2019100
Nov 2019100
Dec 2019100
Jan 2020200
Feb 2020500
Mar 20201600
Apr 2020900
May 2020100
Jun 2020600
Jul 2020300
Aug 20203500
Sep 20202700
Oct 20201000
Nov 20202100
Dec 20201200
Jan 2021300
Feb 20211000
Mar 20211000
Apr 20211200
May 20211600
Jun 2021700
Jul 20211700
Aug 20213300
Sep 20211300
Oct 20211600
Nov 20217400
Dec 20214900
Jan 20226700
Feb 20222000
Mar 20221100
Apr 2022400
May 20222500
Jun 2022100
Jul 2022600
Aug 2022400
Sep 2022200
Oct 2022100
Nov 2022100
Dec 2022100
Jan 2023200
Feb 2023200
Mar 2023300
Apr 2023500
May 2023300
Jun 2023200
Jul 2023200
Aug 2023600
Sep 2023200
Oct 2023400
Nov 2023400
Dec 2023100
Jan 2024600
Feb 2024400
Mar 2024100
Apr 2024500
May 2024400
Jun 2024200
Jul 2024200
Aug 20241200
Sep 20241200
Oct 2024200
Nov 2024300
Dec 2024200
Feb 2025100
Mar 2025300
Apr 2025200
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 58, Issue supplement 1
May 1, 2017
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic value of post-treatment 18F-FDG PET/CT studies in melanoma patients receiving ipilimumab
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Prognostic value of post-treatment 18F-FDG PET/CT studies in melanoma patients receiving ipilimumab
Hoda Anwar, Christos Sachpekidis, Julia Winkler, Jessica Hassel, Uwe Haberkorn, Antonia Dimitrakopoulou-Strauss
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 1088;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prognostic value of post-treatment 18F-FDG PET/CT studies in melanoma patients receiving ipilimumab
Hoda Anwar, Christos Sachpekidis, Julia Winkler, Jessica Hassel, Uwe Haberkorn, Antonia Dimitrakopoulou-Strauss
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 1088;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • Relationship between FDG PETCT imaging and CA 125 levels in treated patients with Ovarian cancers - Can FDG PETCT define and predict the disease burden in clinically suspected recurrence ?
  • Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of SUVmax
Show more Oncology, Clinical Diagnosis Track

Sarcoma/Melanoma Posters

  • Evaluate the cutoff value of 18F-FDG PET parameters to predict lymph node metastasis in the cutaneous melanoma.
  • Value of EORTC criteria in treatment monitoring of melanoma patients receiving ipilimumab
Show more Sarcoma/Melanoma Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire